{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:07:26Z","timestamp":1779912446572,"version":"3.53.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.crad.2026.107355","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:55:09Z","timestamp":1775098509000},"page":"107355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Individualised prediction of HER2 status in colorectal cancer: development and validation of a radiomics prediction model using 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance (18F-FDG PET\/MR)"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9254-8430","authenticated-orcid":false,"given":"Z.","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.crad.2026.107355_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023. CA A","volume":"73","author":"Siegel","year":"2023","journal-title":"Cancer J Clinicians"},{"issue":"3","key":"10.1016\/j.crad.2026.107355_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.crad.2026.107355_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"Journal of the National Cancer Center"},{"issue":"1","key":"10.1016\/j.crad.2026.107355_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","article-title":"Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data","volume":"26","author":"Sung","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2D","key":"10.1016\/j.crad.2026.107355_bib5","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"7","key":"10.1016\/j.crad.2026.107355_bib6","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cncr.31125","article-title":"Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3","volume":"124","author":"Ross","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.crad.2026.107355_bib7","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/bjc.2014.483","article-title":"HER2\/neu testing in primary colorectal carcinoma","volume":"111","author":"Ingold Heppner","year":"2014","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.crad.2026.107355_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.crad.2026.107355_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.crad.2026.107355_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.crad.2026.107355_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2967\/jnumed.114.150318","article-title":"Combined PET\/MR: a technology becomes mature","volume":"56","author":"Wehrl","year":"2015","journal-title":"J Nucl Med"},{"issue":"Supplement 2","key":"10.1016\/j.crad.2026.107355_bib12","doi-asserted-by":"crossref","first-page":"59S","DOI":"10.2967\/jnumed.114.141838","article-title":"Does PET\/MR imaging improve cancer assessments? Literature evidence from more than 900 patients","volume":"55","author":"Czernin","year":"2014","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.crad.2026.107355_bib13","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1007\/s00259-022-05871-0","article-title":"Diagnostic performance of [18F]-FDG PET\/MR in evaluating colorectal cancer: a systematic review and meta-analysis","volume":"49","author":"Mirshahvalad","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.crad.2026.107355_bib14","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.2967\/jnumed.120.254235","article-title":"MR-guided motion-corrected PET image reconstruction for cardiac PET-MR","volume":"62","author":"Munoz","year":"2021","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.crad.2026.107355_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.crad.2026.107355_bib16","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1158\/0008-5472.CAN-22-1183","article-title":"Images are data: challenges and opportunities in the clinical translation of radiomics","volume":"82","author":"Mu","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.crad.2026.107355_bib17","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222988","article-title":"CT radiomics in oncology: insights into the tumor microenvironment of hepatocellular carcinoma","volume":"307","author":"Yoon","year":"2023","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.crad.2026.107355_bib18","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.7150\/thno.30309","article-title":"The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges","volume":"9","author":"Liu","year":"2019","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.crad.2026.107355_bib19","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1007\/s00330-021-08520-6","article-title":"The application of radiomics in predicting gene mutations in cancer","volume":"32","author":"Qi","year":"2022","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.crad.2026.107355_bib20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4149\/neo_2021_200803N807","article-title":"18F-FDG PET\/CT metabolic parameters and HER2 expression in colorectal cancer","volume":"68","author":"Yang","year":"2021","journal-title":"Neoplasma"},{"issue":"2","key":"10.1016\/j.crad.2026.107355_bib21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s00259-021-05441-w","article-title":"Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study","volume":"49","author":"Jiang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"10.1016\/j.crad.2026.107355_bib22","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.crad.2026.107355_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.crad.2026.107355_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000299","article-title":"Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case","volume":"3","author":"Martinelli","year":"2018","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.crad.2026.107355_bib25","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.3390\/ijms22136813","article-title":"Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer","volume":"22","author":"Guarini","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"7","key":"10.1016\/j.crad.2026.107355_bib26","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cncr.31125","article-title":"Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3","volume":"124","author":"Ross","year":"2018","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.crad.2026.107355_bib27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol."},{"issue":"6","key":"10.1016\/j.crad.2026.107355_bib28","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1007\/s00330-018-5763-x","article-title":"Preoperative radiomic signature based on multiparametric magnetic resonance imaging for noninvasive evaluation of biological characteristics in rectal cancer","volume":"29","author":"Meng","year":"2019","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.crad.2026.107355_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00261-022-03759-z","article-title":"Novel multiparametric MRI-based radiomics in preoperative prediction of perirectal fat invasion in rectal cancer","volume":"48","author":"Wang","year":"2023","journal-title":"Abdom Radiol (NY)"},{"issue":"3","key":"10.1016\/j.crad.2026.107355_bib30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00330-018-5683-9","article-title":"Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer","volume":"29","author":"Cui","year":"2019","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.crad.2026.107355_bib31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4251\/wjgo.v16.i3.819","article-title":"T2-weighted imaging-based radiomic-clinical machine learning model for predicting the differentiation of colorectal adenocarcinoma","volume":"16","author":"Zheng","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.crad.2026.107355_bib32","doi-asserted-by":"crossref","first-page":"10603","DOI":"10.2147\/CMAR.S271876","article-title":"MRI-based radiomic signature as a prognostic biomarker for HER2-Positive invasive breast cancer treated with NAC","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.crad.2026.107355_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ultrasmedbio.2025.09.013","article-title":"Prediction of HER2 expression in urothelial carcinoma of the bladder: are ultrasound-based radiomic features significant?","volume":"52","author":"Zhuang","year":"2026","journal-title":"Ultrasound Med Biol"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926026001315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926026001315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:00:24Z","timestamp":1779912024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926026001315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0009926026001315"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2026.107355","relation":{},"ISSN":["0009-9260"],"issn-type":[{"value":"0009-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualised prediction of HER2 status in colorectal cancer: development and validation of a radiomics prediction model using 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance (18F-FDG PET\/MR)","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2026.107355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"107355"}}